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Abbreviations 
 
Heart transplantation (HTx) 
Nonhuman primate (NHP) 
α1,3-galactosyltransferase-knockout (GTKO) 
Endothelial protein C receptor (EPCR) 
C-reactive protein (CRP) 
Interleukin-4 (IL-4) 
Type 2 T helper cell (Th2) 
Interleukin-1 beta (IL-1β) 
Tumor necrosis factor-alpha (TNF-α) 
Interleukin-1 (IL-1) 
Interleukin-6 (IL-6) 
Interleukin-5 (IL-5) 
High mobility group box-1 (HMGB1) 
Interleukin-8 (IL-8) 
Immunosuppressive (IS) 
Interleukin-10 (IL-10) 
Interleukin-1 alpha (IL-1α) 
Human CD46 (hCD46) 
Human thrombomodulin (hTM) 
Central venous catheter (CVC) 
Left atrium (LA) 
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Right atrium (RA)  
Inferior vena cava (IVC) 
Pulmonary artery (PA) 
Data Sciences International (DSI) 
Mycophenolate mofetil (MMF) 
Quantitative real-time polymerase chain reaction (qPCR) 
Relative quantification (RQ) 
White blood cell (WBC) 
Creatine kinase (CK) 
Threshold cycles (Ct) 
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1 Introduction 
 
Over the last few decades, heart transplantation (HTx) has become the preferred 
therapy for end-stage heart failure patients who have tried conventional medical 
therapy or other surgeries without conditions improved. Although mechanical devices, 
including left ventricular assist devices, greatly improved patient survival, 
complications like infections, bleeding and thrombotic complications remain. As 
another train of thought, regenerative medicine has a good success for other tissues, 
but for heart failure stem cell technology is still at the primary stage. As a matter of 
fact, more significant numbers of patients remain who would benefit from heart 
transplantation if donor organs were available. The field of xenotransplantation has 
experienced substantial progress and is considered as a potential solution to this 
problem. 
1.1 History of cardiac xenotransplantation 
The first heart xenotransplantation in humans ever performed was by James Hardy. 
He had been considering heart allotransplantation since he was inspired by the good 
outcome of some patients transplanted with chimpanzee kidneys. In 1964, Hardy 
decided to accomplish the first clinical cardiac transplantation and chose to acquire 
some chimpanzees as possible organ donors. He proposed a recipient who was in a 
semi-comatose state with extensive atheromatous vascular disease, for which he had 
taken amputations of both legs. Because the patient was deteriorating rapidly, Hardy 
made a decision to implant the chimpanzee heart. The heart turned out not to be 
strong enough to support the circulation and eventually failed within two hours[1]. 
However, because the consent form for the operation did not mention that an animal 
heart might be used, Hardy's transplant surgery received opposition from the public 
and medical peers, so he did not perform any further attempt.  
In 1967, on the basis of the experimental research of Cooper [2], the procedure of 
clinical orthotopic cardiac allotransplantation was first established by Christiaan 
Barnard [3]. He later also developed a technique of heterotopic heart 
xenotransplantation, using a chimpanzee and a baboon as donors [4]. The baboon 
heart failed rapidly after surgery, but the chimpanzee heart supported the patient who 
was in postcardiotomy shock after cardiopulmonary bypass for four days. 
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In 1984, the paediatric cardiac surgeon Leonard Bailey transplanted a baboon heart 
orthotopically into an infant girl (Baby Fae) that was born with hypoplastic left heart 
syndrome [5]. The operation was technically successful, but the patient died 20 days 
later because of heart rejection. Although cyclosporine was administered which was 
potent and new at that time, the immunosuppressive therapy was inadequate to 
prevent xenograft rejection. Furthermore, the baboon heart was ABO-incompatible 
with the infant, which might have added to the seriousness of rejection across the 
species barrier. This well-known case drew the public's attention to the shortage of 
accessible human organs for babies. 
Donald Ross and Denton Cooley, two outstanding cardiac surgeons, transplanted pig 
and sheep hearts into patients who were about to die [6, 7]. At that time, Ross did not 
anticipate hyperacute rejection that occurred a few minutes after he performed 
heterotopic cardiac transplantation. Cooley’s sheep heart in further transplantation 
attempts endured the same destiny.  
From these early experiences, researchers have gained a lot of experience with non-
primate mammalian heart and nonhuman primate (NHP) heart transplantation.  
1.2 The immunobiological barriers of cardiac xenotransplantation 
Advances in immunosuppressive (IS) therapy have now made cardiac transplantation 
the gold standard treatment for heart failure treatment. However, cardiac 
xenotransplantation could be a solution to the lack of donor organs. Although 
primates are known to be phylogenetically closer to humans, pigs are now 
considered a more appropriate donor for several reasons[8]: They have organs 
comparable in size and function to those of humans, maintain a high level of 
reproductive efficiency, mature very quickly, and are easy to raise in 
microbiologically-controlled environments with little ethical controversy. Moreover, 
pigs can be genetically modified[9].  
Many experimental studies have been conducted with pigs as donors focusing on 
rejection. In fact, there are three types of rejection after xenotransplantation: 
hyperacute, acute and chronic rejection.  
1.2.1 Hyperacute rejection  
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Hyperacute rejection is the first immunologic barrier for transplantation between 
human or NHP and pig. It starts immediately when the pig coronary arteries are 
perfused by primate blood. The graft is destroyed within 24 hours, but often even 
within the first hour: primate blood contains "natural" anti-pig antibodies that bind the 
vascular endothelial cells of the pig heart and activate the complement cascade. This 
leads to immediate injury of the endothelium, which causes thrombosis in vessels 
and edema that disrupts the function of the endothelium and heart within minutes [10]. 
The rejection is caused by the interaction between a carbohydrate epitope, 
galactose-α1,3-galactose (Gal), from porcine endothelial cells and antibodies present 
in the primate blood[11]. During neonatal life of all primates, these antibodies develop 
and are probably a reaction to micro-organisms that colonize the gastrointestinal tract 
[12, 13]. This response is similar to that in ABO-incompatible allotransplantation 
rejections [14].  
It is possible to reduce this immune reaction by removing naturally preformed 
antibodies [15] and inhibiting the reaction of the complement system [16]. Dalmasso 
and White suggested a different approach to overcome hyperacute rejection: They 
proposed genetic modifications as a strategy to express human complement 
inhibiting proteins on porcine endothelial cells [17, 18]. This was achieved in the 
1990s by a number of groups, creating the first genetically engineered pigs for 
xenotransplantation experiments [8, 18]. In 2001, pigs were genetically modified to 
express human complement-regulatory protein CD46 [19]. When the important role of 
Gal was established, it was suggested that the elimination or knock-out of the Gal 
expression in pigs was a solution to prevent hyperacute rejection. [20, 21]. In 2003, 
this important achievement was done by suppressing the gene for coding α1,3-
galactosyltransferase [22]. The production of genetically engineered pigs is very 
helpful in avoiding the occurrence of hyperacute rejection. 
1.2.2 Acute humoral rejection 
Following transplantation, binding of recipient antibodies to endothelium and 
complement activation promote coagulation, inflammation, and immunity[23]. This 
triggers acute humoral rejection - also called acute vascular rejection - which is 
similar to hyperacute rejection but takes place over several days or weeks.  
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With the development of genetically modified pigs as donors both of these barriers 
have now been overcome. On one hand, pigs that are genetically edited for 
complement regulatory proteins (CRPs) were produced [24]. GTKO pigs prevent 
rejection by expressing human CRPs. On the other hand, the main target for primate 
antibodies has been removed in GTKO pigs [22]. The combination of GTKO and 
human CRPs has more successfully prevented early postoperative failure of pig 
donor organs. [25]. As compared to hyperacute rejection, there are also some 
immune cells involved in acute humoral rejection such as lymphocytes, macrophages, 
natural killer cells, and neutrophils [26, 27].  
1.2.3 Acute cellular rejection 
Antigens from the graft activate an immune response of the recipient, stimulating T-
cells to attack graft heart cells, thus triggering acute cellular rejection [28, 29]. Acute 
cellular rejection usually occurs in the first 3 to 6 months after transplantion.  
Intense cellular graft infiltration is common and occurs early after heart 
allotransplantation, but it was rarely described after heart xenotransplantation. 
Several studies proposed that T-cell response should be more vigorous in the 
transplanted xenograft [30-32].  
1.2.4 Chronic rejection 
Chronic rejection may occur within months or even years after transplantation, and is 
diagnosed clinically by progressing graft failure. Chronic rejection is assumed to 
develop as a consequence of the combined effects of different factors. It is 
suggested that the role of T-cells and antibodies destroys vascular endothelial cells 
which is the initiating factor of chronic rejection. At present, the specific mechanisms 
of chronic rejection after xenotransplant are unclear. 
1.2.5 Coagulation dysfunction 
Even if graft rejection is prevented, another barrier to the success of heart 
xenotransplantation is abnormal coagulation within graft vessels. Thrombotic 
microangiopathy plays an important part in the failure of the graft [33-35].  Fibrin 
deposition and thrombocyte aggregation lead to thrombosis and eventually 
processes to ischemic necrosis injury [33, 34, 36]. 
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Thrombotic microangiopathy is believed to result from activation of the graft’s 
endothelium cells by deposition of antibody and complement fraction. When vascular 
endothelial cells are activated, they transfer from an anticoagulant state to a 
procoagulant state [37]. Several molecular incompatibilities between anticoagulants 
on endothelial cells of pigs and primates are known; incompatible anticoagulants 
cannot inhibit the activation of coagulation factors, which contributes to the 
dysregulation of coagulation between graft and recipient [38].  
It is difficult to overcome coagulation dysfunction after xenotransplantation by 
pharmacotherapy. Genetic engineers made efforts to insert further “anticoagulant” or 
“antithrombotic” transgenes into genetically modified pigs. These include CD39 and 
endothelial protein C receptor resulting in extended graft survival [39].  
An effective genetical modification is the expression of human thrombomodulin on 
porcine endothelial cells which has an inhibitory effect on the coagulation system by 
binding to primate thrombin [40]. Byrne has proved that increased 
immunosuppression therapy is effective in inhibiting 
thrombotic microangiopathy development [41]. 
1.3 Inflammatory response 
There is convincing evidence that inflammatory responses to pig grafts play an 
important role in the failure of the graft after xenotransplantation [42]. Inflammatory 
responses promote coagulation dysfunction after xenotransplantation [42, 43]. Even 
though the manifestation of the inflammatory response in xenotransplantation is not 
well explained, but it can be associated with the increase of white blood cells, 
especially neutrophil [42]. Also, an elevation of C-reactive protein (CRP) is a clinically 
significant inflammatory marker [44]. Li’s study monitoring CRP in NHP recipients 
with pig grafts proved tocilizumab reduce the inflammatory response after 
xenotransplantation [45]. 
Inflammatory cytokines are molecules which work as inflammatory mediators. They 
are excreted from different cell types and can be measured in the blood. Changes in 
cytokine production in the tissue can be quantified by gene expression analysis. The 
following cytokines are involved in inflammation: 
1.3.1 IL-4 
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Interleukin-4 (IL-4) is an anti-inflammatory cytokine of the type 2 T helper cell (Th2) 
subtype, secreted by immune cells, including lymphocytes and mast cells. Cytokine 
IL-4 has been shown to be involved in the cardiac fibrosis process, which leads to 
reduced myocardial compliance and ultimately a cardiac failure; Interleukin-1 beta 
(IL-1β) is also associated with this progress [46, 47]. The pro-inflammatory response 
of tumor necrosis factor-alpha (TNF-α), Interleukin-1(IL-1), and Interleukin-6(IL-6) are 
also inhibited by IL-4[48].  
1.3.2 IL-5 
As IL-4, interleukin-5 (IL-5) is also produced mainly by activated Th2 and mast cells, 
their genes are both located on the same chromosome within a cytokine gene cluster. 
IL-5 is a cytokine that plays a central role in eosinophil development, activation and 
survival[49]. Proteins released by eosinophil may influence coronary atherosclerosis 
independent from the IL-1 and IL-6 pathways [50]. IL-5 is also an essential cytokine 
associated with human myocarditis [51]. Braun’s study revealed that IL-5 and 
eosinophils are related to the promotion of rejection after cardiac allotransplantation 
[52]. 
1.3.3 IL-6 
Interleukin-6 (IL-6) is created by a multitude of cells including fibroblasts, monocytes, 
T-cells, B-cells, endothelial cells and mesangial cells [53]. IL-6 is an interleukin that 
functions as both pro-inflammatory and anti-inflammatory cytokine[54]. Many articles 
have already explained the key roles of IL-6 in inflammation and allotransplantation 
[55, 56]. It has been shown that excessive production of IL-6 stimulates B cells to 
generate antibodies which eventually results in graft failure in transplantation [57]. 
Both Ezzelarab’s and Gao’s studies suggested that IL-6 might promote the 
occurrence of coagulation dysregulation and inflammation response after 
xenotransplantation [42] [58]. Ezzelarab also indicated that IL-6 was increased 
without immunosuppressive treatment in pig-to-baboon heart xenotransplantation 
[42].  
Li’s experiments in rat-to-mouse cardiac xenotransplantation indicated that inhibition 
of IL-6 using an anti-high mobility group box-1 (HMGB1) antibody might prolong the 
survival of cardiac xenografts [59]. In the pig-to-monkey islet model, Min observed 
that blockage of IL-6 signalling could not prolong the survival of porcine pancreatic 
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islets in monkeys (treated with tocilizumab) but decreased levels of CRP [60]. Iwase 
showed that tocilizumab therapy decreased CRP in baboons with a porcine artery 
patch or heart transplant [61]. Tocilizumab therapy also extended survival time of 
kidney xenografts of transgenic pigs [62].  
1.3.4 IL-8 
Interleukin-8 (IL-8) is a chemokine created by macrophages, epithelial cells, and 
endothelial cells. IL-8 is an important pro-inflammatory chemokine that plays a 
primary role in the activation of neutrophils during inflammation response. French‘s 
study, in both ex vivo pig lung perfusion model and in-vivo pig-to-baboon lung 
transplantation experiments, showed that IL-8 activated human neutrophils and 
increased their adherence to pig aortic endothelial cells[63]. In this same trial, pig IL-8 
increased in the ex vivo model but not in the vivo experiments, whereas in the human 
and baboon models IL-8 was similarly elevated. Ezzelarab reported that baboon IL-8 
levels were increased after pig-to-baboon artery patch transplantation, but no 
elevation was observed after pig heart or kidney xenotransplantation [42]. In addition, 
IL-8 was elevated with no immunosuppressive (IS) treatment in artery patch 
recipients, but IL-8 was reduced with IS therapy. Iwase showed post-transplant levels 
of IL-8 were elevated when no anti-inflammatory agent was administered [64].  
1.3.5 IL-10 
Interleukin-10 (IL-10) is known to be produced by monocytes, T cells and B cells. It is 
a pleiotropic anti-inflammatory cytokine. Kaur’s [65] study indicated that a decrease in 
IL-10 correlates with depressed cardiac function. Krishnamurthy et al. demonstrated 
that IL-10 not only has as an anti-inflammatory effect but also improves left 
ventricular function by inhibiting cardiac fibrosis and remodeling [66]. Other 
researchers, however, did not find an association between genotypes of IL-10 and 
rejection or heart failure after transplants [67].   
1.3.6 TNF-α 
Investigations have shown that TNF-α is a key pro-inflammatory cytokine and an 
essential part of the innate immune system. It was produced by immune cells, such 
as activated macrophages and lymphocytes, endothelial and epithelial cells, smooth 
muscle cells, and heart myocytes. TNF-α can be released from the myocardium 
when the heart experiences pressure or volume overload [68]. TNF-α leads 
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to hypertrophy and cardiac enlargement when it is chronically overexpressed in the 
myocardium[69]. Numbers of researches indicated that TNF-α in cardiac transplant 
recipients was elevated without histological evidence for rejection [70, 71].  Xu 
reported that rejecting porcine hearts secreted TNF-α in a pig-to-baboon orthotopic 
cardiac xenotransplant model [72]. Additionally, Ashton-Chess demonstrated that 
upregulated TNF-α expression was observed in both non-immunosuppressed 
baboons and those treated with immunoadsorption after transplantation of hCD55-
transgenic pig hearts [73]. In both kidney and islet xenotransplantation models, 
blockade of TNF-α increased the postoperative survival time of xenografts [62, 74].  
1.3.7 IL-1α 
Interleukin-1 alpha (IL-1α) is a potent inflammatory cytokine of the IL-1 family 
involved in various immune responses. It is also known as hematopoietin 1 and 
produced by macrophages, neutrophils, epithelial cells, and endothelial cells. IL-1α is 
constitutively present in most healthy cells as a precursor protein and released after 
an injury like alarm bell[75]. Dead cardiomyocytes release IL-1α that can trigger a 
post-infarction inflammatory response [76]. 
1.3.8 IL-1β 
IL-1β is a pro-inflammatory cytokine produced by many cells, such as macrophages, 
NK cells, monocytes, and neutrophils, myeloid cells, fibroblasts, and endothelial cells. 
IL-1β was found to be increased postoperatively after xenotransplantation in vitro 
models [58]. Moreover, it has been shown that IL-1β correlated with the complete 
range of organ ischemia/reperfusion injury, from acute rejection to chronic allograft 
dysfunction [77-79]. One of the early studies of transplant inflammation discovered 
that there was a significant rise in IL-1β expression from cardiac allografts with 
rejection compared to allograft controls [80]. 
1.3.9 Pro- and anti-inflammatory cytokines 
The appropriate concept of anti-inflammatory cytokines is a group of molecules that 
regulates the cytokine response to inhibit IL-1, TNF-α synthesis. The interplay 
between pro- and anti-inflammatory cytokines characterizes inflammation. The 
classification of cytokines is listed in table 1. Pro-inflammatory cytokines assist with 
infection resistance and can lead to systemic inflammation[81]. In some in vitro 
studies related to xenotransplantation, all of the cytokines/chemokines, IL-6, IL-1β, 
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and TNF-α, are likely to stimulate inflammation and coagulation in response to a 
xenograft [58]. An increase of cytokines after xenotransplantation was observed in 
the absence of immunosuppressive therapy but not when immunosuppressive agents 
were administered[42]. Ezzelarab[82] indicated that the effect of immunosuppressive 
therapy on anti-inflammatory cytokines in xenotransplant recipients was unclear and 
required further inquiry. 
1.3.10 Acute and chronic inflammatory cytokines 
It is possible to divide inflammatory cytokines into two groups (table 1): those 
engaged in acute inflammation and those responsible for chronic inflammation. IL-1, 
TNF-a, IL-6, and IL-8 play an important role in acute inflammation. The chronic 
inflammation cytokines group can be further devided into cytokines that mediate 
humoral reactions like IL-4, IL-5, and IL-6, as well as those that mediate cellular 
reactions like IL-1, IL-10, and TNF-a. Some cytokines, like IL-1, contribute 
considerably to both chronic and acute inflammation. 
Table 1 Classification of inflammatory cytokines 
pro-inflammatory anti-inflammatory acute inflammatory chronic inflammatory 
IL-1α IL-4 IL-1α IL-1α 
IL-1β IL-5 IL-1β IL-1β 
IL-6 IL-6 IL-6 IL-4 
IL-8 IL-10 IL-8 IL-5 
TNF-α  TNF-α IL-6 
   IL-10 
   TNF-α 
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2 Materials and methods 
2.1 Heart xenotransplantation 
2.1.1 Animals 
In this study, pigs of the breeds large white/landrace (Sus scrofa) that had a 
homozygous α1,3-galactosyltransferase-knockout (GTKO) and were heterozygous 
transgenic for human CD46 (hCD46) and human thrombomodulin (hTM) were used 
as organ donors (age 7-12 weeks, weight 8-23 kg, n=16). Captive-bred baboons 
served as organ recipients (age 4-12 years, weight 11-25 kg, n=16). The body 
weights of donor and recipient were matched to ensure similar heart sizes at the time 
of transplantation. Seven days before transplantation, physical examination and 
transthoracic echocardiography were performed to examine the cardiac function and 
exclude congenital anomalies, such as aortic insufficiency.  
The pigs originated from the Institute for Molecular Animal Breeding and 
Biotechnology, Gene Center, Faculty of Veterinary Medicine, Ludwig-Maximilians-
University, Munich, Germany), the baboons from the Germany Primate Centre (DPZ), 
Göttingen, Germany. Their health condition was examined several times before and 
after they were transferred to the Walter-Brendel-Centre where the experiments were 
performed. Blood samples were taken for analysis when they arrived. The baboons 
were held together in one animal facility and regularly received dry food, fresh fruit, 
vegetables, and drinking water at their free disposal. Postoperatively, each of 
baboons was kept in a big cage specifically designed and constructed to allow post-
operative treatment.  
Before transplantation, the recipient baboon was sedated by intramuscular 
administration of 0.3-0.5 mg/kg midazolam (Midazolam-ratiopharm; ratiopharm 
GmbH, Germany) and 6-8 mg/kg ketamine hydrochloride (Ketavet 100 mg/mL; Pfizer 
Deutschland GmbH, Germany) [83]. A peripheral venous line was inserted for the 
preoperative medical treatment (see 2.1.3) and blood sampling. Baboons underwent 
a physical examination for signs of contraindications for surgery. 
Two days before cardiac transplantation, the baboon received a central venous 
catheter (CVC), which was implanted into the left jugular vein and tunnelled 
13 
 
subcutaneously to the side of the thoracic cage. Postoperatively, a tethering system 
with a baboon jacket and swivel was used to hide and protect the CVC and the 
infusion system from damage by the animal. The infusion lines connected to CVC 
were passed via a swivel through the roof of the cage. In this way, continuous 
administration of medication was possible. 
2.1.2 Surgical procedures 
On the day of the operation, general anaesthesia of donor pig was induced by an 
intravenous bolus of 20 mg propofol and 0.05 mg fentanyl. To maintain anaesthesia, 
propofol (0.12 mg kg−1 min−1) and bolus administrations of fentanyl (2.5 μg kg−1, 
repeated every 30 min) were used. After medial thoracotomy and systemic 
heparinization (500 IU kg−1), the ascending aorta was exposed and cannulated. The 
heart was emptied by closing of the superior and inferior vena cava. Ischemic and 
non-ischemic organ preservation methods were used:  
1. For experiments PAV1 to PAV4, 20 ml kg−1 crystalloid cardioplegic solution 
(histidine-tryptophan-ketogluterate (custodial HTK, Dr. Franz Köhler Chemie) or 
University of Wisconsin (Belzer’s UW) solution) at 4° C was infused into the coronary 
arteries via the ascending aorta.  The right and left atrium appendices were opened 
for reducing the pressure. The heart was then harvested, submerged in the cold 
cardioplegic solution.  
2. For experiments PAV5 to PAV16, an oxygenated 8°C cold albumin-containing 
hyperoncotic cardioplegic nutrition solution with hormones and erythrocytes 
preservation medium (based on Steen SolutionTM, a sterile, non-pyrogenic 
physiological salt solution containing human serum albumin and dextran 40) was 
infused into the coronary arteries via the ascending aorta, following a protocol 
described by Steen et al [84]. The heart was then excised and transferred into a 
heart preservation system (consisting of a pressure- and flow-controlled roller pump, 
an O2/CO2 exchanger, a leukocyte filter, an arterial filter and a cooler/heater unit), 
where it was continuously perfused with preservation medium, an oxygenated 
albumin-containing hyperoncotic cardioplegic nutrition solution with hormones and 
erythrocytes. In this group, intermittent perfusion of the heart was continued during 
implantation. 
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Meanwhile, general anesthesia of the recipient baboon was induced by an 
intravenous bolus of 2.0-2.5 mg/kg propofol (Propofol®-Lipuro 2%; Melsungen, 
Germany) and 8 μg/kg fentanyl (Fentanyl-Janssen 0.5 mg; Neuss, Germany). Blood 
pressure, heart rate, and electrocardiography were monitored. Endotracheal 
intubation was performed with a cuffed endotracheal tube (5.0-7.0 mm diameter; 
Mallinckrodt, Athlone, Ireland). Anaesthesia was maintained with continuous infusion 
of propofol at 0.16±0.06 mg/kg/min [83].  
After medial thoracotomy, heparin (500 IU kg−1; Ratiopharm) for heparinization was 
given and the heart-lung machine was connected to both venae cavae and the 
ascending aorta. The ascending aorta was cross-clamped, the heart of the recipient 
was excised at the atrial levels, and both large vessels were cut. The heart of the 
porcine was transplanted using the method of Shumway and Lower [85]: The donor 
graft was implanted beginning with the left atrium (LA) anastomosis. The donor right 
atrium (RA) was opened by incising it from the inferior vena cava until the base of the 
right atrial appendage; then the anastomosis of the RA was established. The donor 
and recipient pulmonary artery (PA) were linked together with an anastomosis. Using 
the same end-to-end anastomosis method, the donor heart’s ascending aorta was 
connected by incising to the recipient’s aorta.  
At the end of the procedure, a telemetric monitoring system (Data Sciences 
International, DSI) was implanted. The telemetry system was used for postoperative 
assessment of graft function and recipient hemodynamic monitoring (see 2.1.4).  
2.1.3 Perioperative treatment 
Immunosuppressive (IS) regimen for all recipient animals included an induction 
therapy which comprised anti-CD20 antibody (mabthera, Roche Pharma) and ATG 
(thymoglobuline, Sanofi-Aventis). Maintenance IS therapy consisted of 
methylprednisolone (urbasone soluble, Sanofi-Aventis), mycophenolate mofetil 
(CellCept, Roche) and either an anti-CD40 antibody (mouse/rhesus chimeric IgG4 
clone 2C10R4, NIH Non-human Primate Reagent Resource, Mass Biologicals; 
courtesy of K. Reimann) or humanized anti-CD40L PASylated Fab (XL-Protein and 
Wacker-Chemie).  
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Anti-inflammatory therapy included TNF inhibitor (Enbrel, Pfizer), IL-1-receptor 
antagonist (Kineret, Swedish Orphan Biovitrum), and IL-6-receptor antagonist 
(RoActemra, Roche). 
Additive treatments included unfractionated heparin (heparin-natrium-25000-
Ratiopharm, Ratiopharm), ganciclovir (cymevene, Roche), C1 esterase inhibitor 
(bioinert, CSL Behring), epoetin beta (neorecormon 5000IU, Roche P), acetylsalicylic 
acid (aspirin, Bayer Vital), and cefuroxime (cefuroxim, Hikma).  
Antihypertensive medication including enalapril (Enahexal, Holzkirchen) and 
metoprolol (Beloc, AstraZeneca) was administered postoperatively, aiming at mean 
arterial pressures of 80 mmHg and heart rates of 100 beats per minute). Additionally, 
PAV10 to PAV16 received temsirolimus as daily short intravenous infusions, aiming 
at rapamycin trough levels of 5-10ng/ml. 
2.1.4 Postoperative monitoring 
The health condition of the animal was monitored daily by clinical parameters such as 
the animal’s behavior, appetite, urination, defecation, and respiration rate. Any 
abnormalities and changes in clinical manifestations were recorded. The following 
parameters were assessed and continuously monitored by DSI: systolic, diastolic and 
mean pressure of left ventricle, electrocardiography (ECG), systolic and diastolic 
pressure of the aorta, heart rate derived from pressure waves of the left ventricle, 
heart rate derived from ECG, and body temperature.  
At least once a week, the baboon was sedated for a clinical examination and an 
assessment of the function and growth of the porcine graft by echocardiography. 
Furthermore, postoperative pericardial or pleural effusion could be diagnosed non-
invasively by ultrasound.  
Blood was sampled via the CVC and analyzed in the Department of Clinical 
Chemistry of the University Hospital of Munich. Serum chemistry, haematology, 
coagulation, serology, complement, therapeutic drug blood concentration was 
measured regularly. Inflammatory markers were: WBC count, neutrophils count, 
lymphocytes count, CRP, IL-6.  The serum concentration of cardiac injury markers 
(Troponin T, CK) was measured to identify myocardial damage. 
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2.1.5 Endpoints of the study and sample collection 
The primary endpoint was the postoperative survival of the recipient baboons after 
pig-to-baboon cardiac xenotransplantation. If graft function and general condition of 
the recipient deteriorated (see 2.1.4), the animals were euthanized in general 
anaesthesia by anaesthetic overdose according to governmental regulations. The 
recipients were also euthanized after reaching a survival time of 90 days (PAV1-
PAV14) and six months (PAV15, PAV16), respectively, according to study protocol. 
The hearts were explanted immediately after euthanization. Both left and right 
ventricle myocardium were sliced into 5*5mm small squares and immediately placed 
in liquid nitrogen. Long-term preservation was achieved by storage at -80°. As 
negative controls, three non-transplanted hearts from age- and weight-matched pigs 
were used. Samples were collected using the same methods as described for 
transplanted animals. 
2.2 RNA Extraction 
2.2.1 Extraction methods 
Total RNA was isolated from 32 frozen samples of left and right ventricle myocardium 
of each post mortem heart using the RNeasy Mini Kit (Qiagen). A maximum amount 
of 30 mg of frozen tissue was processed. The samples to be processed were placed 
into lysis tubes (Analytik Jena) with 500μl Buffer RLT (Qiagen) for disruption and 
homogenization: Homogenization was done twice for 30 seconds using a SpeedMill 
PLUS (Analytik Jena) and cooling on ice for 1 hour after homogenization according to 
the instructions. After homogenization, the lysate was centrifuged at 14,500 ×g for 3 
min. The supernatant was carefully transferred by pipetting to a new RNase-free 
micro centrifuge tube. 500μl of 70% ethanol was added to the lysate and mixed 
immediately. 700 μl of the sample, including any precipitate, was transferred to an 
RNeasy spin column, placed in a 2 ml collection tube and centrifuged at ≥8000 x g for 
15 s. 700 μl buffer RW1 (containing a guanidine salt and ethanol, used as a washing 
buffer, Qiagen) was added to the RNeasy spin column and centrifuged at ≥8000 x g 
(≥10,000 rpm) for 15 s to wash the spin column membrane. 500 μl buffer RPE (a mild 
washing buffer to remove traces of salts, Qiagen) were added to the RNeasy spin 
column and centrifuged for 15 s at ≥8000 x g. To wash the spin column membrane, 
500 μl buffer RPE was added to the RNeasy spin column. The RNeasy spin column 
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was moved in a new 2 ml collection tube and discarded the old collection tube with 
any flow-through. The spin column was moved in a new 1.5 ml collection tube, 30μl 
RNase-free water was added directly on the spin column membrane and the 
collection tube was centrifuged for at ≥8000 x g for 1 min to elute the RNA.  
2.2.2 Quantitation and storage of isolated RNA 
RNA concentration and purity were assessed by ultraviolet spectroscopy method. 1 
μL of the RNA solution was analyzed with a Nanodrop 2000c spectrophotometer 
(ThermoScientific). A260 and A280 readings were used to determine the 
concentration (μg/μL) and assess purity (A260:A280). The concentration of each 
RNA sample was measured and used to calculate volumes of 1μg RNA. Accurate 
volumes of 1μg RNA solution were transferred into 200 μl tubes for storage (-80°C). 
2.3 Reverse transcription 
RNA was reverse-transcripted to cDNA using the Thermo Scientific Maxima H Minus 
Reverse Transcriptase kit (Thermo Fisher). 1 μg of RNA solution was diluted by 
nuclease-free water to reach a total volume of 16 μL. Incubated at 65°C for 15 
minutes. 4 μL Maxima H Minus cDNA synthesis master mix was added for a final 
volume of 20 μl. The tubes were placed in the Applied Biosystems 2720 Thermal 
Cycler (Thermo Scientific) for synthesis using a protocol of 25°C for 10 minutes, 50°C 
for 15 minutes, 85°C for 5 minutes, and finally 4°C until removal from the machine. 
The cDNA was then diluted in 100 μL with sterile nuclease-free water and stored at -
20°C. 
2.4 Quantitative real-time PCR (qPCR) 
2.4.1 Primers 
Eight inflammatory genes (IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α, IL-1α, and IL-1β) were 
investigated for gene expression analysis by real-time PCR. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as a housekeeping gene to normalize 
the data. Primer sequences for all genes, lengths of sequences, melting temperature 
(Tm) of the primers, and guanine-cytosine content (GC content) of sequences are 
shown in Table 2.1. All primer sequences were obtained from Eurofins Scientific. 
Although we used pig specific primers for qPCR analysis, cross-reaction between pig 
and baboon cannot be completely eliminated. 
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Table 2.1 Primers used in qPCR 
Primer Pair Sequence (5′→3′) Length 
(bp) 
GC 
content 
TM 
(°C) 
Amplified 
Gene 
F.GAPDH 
S.scofra 
TTCCACGGCACAGTCAAGGC 20 60% 61.4 GAPDH 
R.GAPDH 
S.scofra 
GCAGGTCAGGTCCACAAC 18 61.1% 58.2 GAPDH 
IL-4  Ex1 
F1 
GCAACTTCGTCCACGGACAC 20 60% 61.4 IL-4 
IL-4  Ex3 
R1 
TTTGCCATGCTGCTCAGGTT 20 50% 57.3 IL-4 
IL-5  Ex1 
F1 
GCCTACGTTAGTGCCATTGCTG 22 54.5% 62.1 IL-5 
IL-5  Ex4 
R1 
TCTCCATCTTTCCCCTCCACA 21 52.4% 59.8 IL-5 
IL-6  Ex4 
F1 
ATCACCACCGGTCTTGTGGA 20 55% 59.4 IL-6 
IL-6  Ex5 
R1 
CCTCAGGCTGAACTGCAGGA 20 60% 61.4 IL-6 
IL-10 Ex1 
F1 
CCTTCGGCCCAGTGAAGAGT 20 60% 61.4 IL-10 
IL-10 Ex4 
R1 
CGGCCTTGCTCTTGTTTTCA 20 50% 57.3 IL-10 
IL-8  Ex1 
F1 
CCAAACTGGCTGTTGCCTTC 20 55% 59.4 IL-8 
IL-8  Ex3 
R1 
CTGCACCCACTTTTCCTTGG 20 55% 59.4 IL-8 
TNF-α Ex1 
F1 
GGCCCCCAGAAGGAAGAGTT 20 60% 61.4 TNF-α 
TNF-α Ex4 
R1 
ATGCGGCTGATGGTGTGAGT 20 55% 59.4 TNF-α 
IL-1α Ex5 
F1 
TTCGAGACCCGTCAGGTCAA 20 55% 59.4 IL-1α 
IL-1α Ex7 
R1 
ATGGGCGGCTGATTTGAAGT 20 50% 57.3 IL-1α 
IL-1β Ex3 
F1 
TGATGGCCCCAAAGAGATGA 20 50% 57.3 IL-1β 
IL-1β Ex5 
R1 
GCACGTTGGCATCACAGACA 20 55% 59.4 IL-1β 
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2.4.2 Quantitative real-time polymerase chain reaction (qPCR) 
QPCR amplifications were performed on each cDNA sample in triplicate within wells 
of a 96-well PCR plate. A negative control reaction containing no cDNA was included 
to determine if there was any DNA contamination of the reactions. A PowerUp™ 
SYBR™ Green Master Mix (Thermal fisher) containing the following reagents were 
prepared for each primer: 
 
Table 2.2 Composition of master mix 
Component Volume 
SYBR® Green qPCR Master Mixes   5μl 
Nuclease-free H2O 2μl 
Forward Primer 0.5μl 
Reverse Primer 0.5μl 
Total volume 8 μl 
 
2μl of cDNA was added to each well of a 96 well PCR plate to create a final reaction 
volume of 10μl. The plate was sealed with an adhesive cover, then centrifuged briefly 
to spin down the contents and eliminate any air bubbles. qPCR was performed in 
“standard cycling - mode using a StepOnePlus™ Real-Time PCR System (Applied 
Biosystems) set as following: 
 
Table 2.3 qPCR steps 
Step Temperature Duration Cycles 
UDG activation 50°C  2 minutes Hold 
DNA polymerase 95°C 2 minutes Hold 
Denature 95°C 15 seconds 40 
Anneal/extend 60°C 1 minute 40 
 
A default dissociation step (melt curve stage) was performed directly after the real-
time PCR run. The following settings were used: 
 
Table 2.5 Dissociation curve conditions (melt curve stage) 
Step Ramp rate Temperature Time 
1 1.6°C/second 95°C 15 seconds 
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2 1.6°C/second 60°C 1 minute 
3 0.15°C/second 95°C 15 seconds 
 
Table 2.6 qPCR instrument set up 
Set up for instruments  
Experiment type Standard curve 
Reagent SYBR™ Green reagents 
Reporter SYBR™ 
Quencher None 
Ramp speed Standard 
Melt curve ramp increment Continuous 
 
2.5 Statistical analysis 
For calculation of the baseline and threshold cycles (Ct) for the amplification curves, 
the instrument software (Steponeplus) was used. 
The threshold cycle (Ct) is the cycle number at which the fluorescence generated 
within a reaction crosses the threshold line, usually set sufficiently above background 
fluorescence (Applied Biosystems).  The Ct is a relative measure of the target 
concentration in the PCR reaction; high Ct indicates a low concentration of template, 
whereas low Ct indicates a high concentration of target molecules in the sample. 
If the gene did not amplify during a qPCR reaction all three times, the Ct value of 
such an experimental reaction was set to 0, indicating that there was no expression 
of this gene in the respective experiment. 
Relative expression was quantified using the ‘Comparative Quantitation’ method or 2-
ΔΔCt method[86], similar to the previously published ΔΔCt method[87]. ΔΔCt enables 
the dynamic amplification efficiency of each run to be determined by taking into 
account the take-off point, similar to the Ct (Applied Biosystems). The software 
automatically calculates the take-off point for each amplified target. Relative 
expression was quantified as follows: 
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To calculate the ΔCt value or normalized value (i.e., relative expression to GAPDH), 
the means of triplicate Ct values for GAPDH were subtracted from the means of 
triplicate Ct values for each target using formula (1):  
(1) ΔCt = Ct TARGET – Ct GAPDH. 
To calculate the ΔΔCt value, the ΔCt value of the control sample was subtracted from 
the ΔCt of the experimental sample using formula (2): 
(2) ΔΔCt =ΔCt CONTROL - ΔCt SAMPLE  
Relative quantification (RQ) is calculated by using formula (3):  
(3) RQ=2-ΔΔCt  
ΔΔCt presents the size and direction of the gene expression change. A ΔΔCt < 0 
indicates an overexpression of the target gene as compared to the control, whereas 
a ΔΔCt > 0 indicates an underexpression. ΔΔCt was used for correlation with other 
linear parameters, such as laboratory markers and postoperative survival.  
RQ is the relative fold change; an RQ of 2 describes an 2-fold increase of the target 
gene as compared to control. If RQ < 1, the gene was down-regulated. If RQ > 1, 
the gene was up-regulated. RQ was used for comparison between different 
experiments and genes.  
Data analysis including statistics and graphs were performed with Microsoft office 
GraphPad Prism 8.0 software. Due to the small number of experiments normal 
distribution of data was assumed. The statistical significance of RQ or fold-change 
was calculated using the Student’s t-test. A P value of less than 0.05 was considered 
statistically significant. The calculation of ΔΔCt and RQ of control heart was used in 
the same methods. 
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3. Result 
3.1 Postoperative survival 
Survival times of 16 xenotransplanted baboons are shown in Figure 3.1. The longest 
survival was 195 days (PAV16). The shortest survival was one day (PAV2, PAV4, 
and PAV6). The median survival of baboons was 61.3 days. The maximum survival 
time was only 30 days in the first 8 experiments; the longest survival time was seen 
in the last two experiments.  
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Figure 3.1 Postoperative survival after orthotopic cardiac xenotransplantation 
3.2 Inflammatory markers in peripheral blood 
Laboratory results of CRP, IL6, white blood cell count, lymphocytes and neutrophils 
are shown in Figure 3.2. On the last day of the experiments, the mean CRP 
concentration was 2.1 ± 2.1 mg/dl. High levels of CRP were observed in PAV 1 (7.5 
mg/l) and PAV 11 (6.1 mg/l), all other recipient baboons had a normal CRP 
concentration (＜5 mg/l). Mean serum concentration of IL-6 was 275.6 ± 474pg/ml 
(Figure 3.2.b). The normal range of IL-6 in human adults is 5-15 pg/ml. 
Mean level of white blood cell (WBC) count was 8.1 ± 6 ×109/L (Figure 3.2.c), 
absolute neutrophil count was 5.8 ± 5 ×109/L (Figure 3.2.d), absolute lymphocyte 
count was 1 ± 0.9 ×109/L (Figure 3.2.e). Blood cell counts were all in the normal 
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human ranges (WBC count: 4.5-11.0 × 109/L; Neutrophils count: 2.0-7.0×109/l; 
lymphocytes count:1.0-3.0×109/l). PAV1, PAV4, PAV6, PAV7, and PAV 8 had 
abnormally high levels of WBC count and Neutrophils count. PAV3 and PAV14 had 
abnormally low levels of both. There were differences between the first 9 and last 7 
experiments in WBC count (p=0.01) and Neutrophils count (p=0.008).  
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Figure 3.2 Laboratory results of xenotransplant recipients on the last day of the experiment. 
Serum concentration of CRP (a), IL6 (b), WBC count (c), neutrophil count (d), lymphocyte 
count (e). 
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3.3 Markers of myocardial damage in peripheral blood 
Mean creatine kinase (CK) concentration was 6599 ± 9708 IU/L (Figure 3.3.a), which 
was higher than the normal range (5 to 25 IU/L). There was a difference between the 
first 9 and the last 7 experiments in serum CK values (p=0.027). The mean serum 
concentration of Troponin T was 2.53 ± 5.79 ng/L (Figure 3.3.b). The normal range is 
less than 0.015 ng/L. 
PA
V1
PA
V2
PA
V3
PA
V4
PA
V5
PA
V6
PA
V7
PA
V8
PA
V9
PA
V1
0
PA
V1
1
PA
V1
2
PA
V1
3
PA
V1
4
PA
V1
5
PA
V1
6
0
10000
20000
30000
a
C
K
（
IU
/L
）
PA
V1
PA
V2
PA
V3
PA
V4
PA
V5
PA
V6
PA
V7
PA
V8
PA
V9
PA
V1
0
PA
V1
1
PA
V1
2
PA
V1
3
PA
V1
4
PA
V1
5
PA
V1
6
0.01
0.1
1
10
100
b
T
ro
p
o
n
in
 T
(n
g
/l
)
  
Figure 3.3 Laboratory results of xenotransplant recipients on the last day of the experiment. 
The serum concentration of CK (a) and troponin T (b) 
3.3 Inflammatory gene expression in the graft 
RQ of all measured inflammatory genes (IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α, IL-1α, 
and IL-1β) are shown in Figure 3.4. Comparative analysis of gene expression (Figure 
3.5) between left and right ventricle revealed no significant difference in all 
experiments (P＞0.05). The average RQ of left and right ventricle was calculated to 
present fold changes in each graft gene expression (Figure 3.6). 
In figure 3.7, the gene expression level of each experiment is depicted. There were 
no statistically significant difference of IL-4 (1.11 ± 2.46, p=0.861), IL-5 (14.11 ± 
31.05, p=0.102), IL-6 (19.10 ± 49.95, p=0.158), IL-10 (1.37 ± 2.53, p=0.248), TNF-α 
(6.63 ± 12.84, p=0.089), IL-1α (1.38 ± 2.44, p=0.538) and IL-1β (1.59 ± 2.50, 
p=0.285). Only IL-8 (4.28 ± 5.54, p=0.025) was upregulated among all 8 inflammatory 
genes (Figure3.6).  
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Figure 3.4 Quantification of 8 different gene expression of left and right ventricle (left is grey; 
the right is black) in the graft. Absence of column indicates no gene expression. 
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Figure 3.5 Gene expression of the graft after cardiac xenotransplantation. There were no 
significant differences between the left and right ventricles. 
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Figure 3.6 Gene expression of the graft after cardiac xenotransplantation. Mean RQ of each 
gene plotted. Absence of column indicates no gene expression. 
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Figure 3.7 Gene expression of the graft after cardiac xenotransplantation. Comparison to 
control for each gene. 
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The colour map (Figure 3.8) displays the fold changes of each gene in each 
experiment more clearly. The mean fold change of gene expression was calculated 
for each experiment (Figure 3.9). In most experiments there were no significant 
changes (Figure 3.10): PAV1 (14.79 ± 39.59, p=0.35), PAV2 (1.10 ± 1.44, p=0.85), 
PAV3 (29.56 ± 55.68, p=0.17), PAV4 (29.60 ± 45.86, p=0.10), PAV6 (3.77 ± 4.01, 
p=0.07), PAV7 (1.24 ± 1.89, p=0.73), PAV8 (0.59 ± 0.79, p=0.16), PAV9 (2.12 ± 2.17, 
p=0.43), PAV10 (0.60 ± 0.85, p=0.21), PAV13 (2.02 ± 2.21, p=0.21), PAV14 (0.71 ± 
1.01, p=0.28), PAV15 (2.26 ± 5.08, p=0.57). PAV5 (11.24 ± 8.80, p=0.0053) was the 
only experiment in which the mean of all observed gene expressions was 
upregulated. PAV11 (0.08 ± 0.11, p<0.0001), PAV12 (0.05 ± 0.05, p<0.0001) and 
PAV16 (0.30 ± 0.66, p= 0.0092) were three experiments, in which the mean of all 
gene expressions was downregulated.  
 
Figure 3.8 Colour map of gene expression. Red colour indicates gene upregulation, blue 
colour gene downregulation. 
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Figure 3.9 Gene expression of the graft after cardiac xenotransplantation. Mean RQ of each 
experiment plotted. Absence of column indicates no gene expression. 
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Figure 3.10 Gene expression of the graft after cardiac xenotransplantation. Comparison to 
control for each experiment. (*p＜0.05, **p＜0.001) 
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3.4 Correlation between gene expression and survival  
There was a significant correlation between ∆∆Ct of all genes and postoperative 
survival (figure 3.11). There were significant correlations between survival time and 
∆∆Ct of IL-4 (r=-0.52, p=0.048), IL-10 (r=-0.58, p=0.037) and IL-1β (r=-0.65, p=0.007) 
(figure 3.12).  
Grouped by more or less than 40 days of survival, the differences of these 
experiments were examined by t-test. Except for IL-5 and TNF-α, significant 
differences were found in the other 6 genes (Figure 3.13): IL-1β (0.94±5.69， -
7.89±3.22， p=0.004), IL-4 (0.144±7.45，-7.55±2.16，p=0.021), IL-6 (1.72±5.11，-
3.32±2.96，p=0.034), IL-8 (3.12±4.89，-1.89±2.96，p=0.029), IL-10 (1.30±5.22，-
6.99±2.93，p=0.026), and IL1-α (0.39±5.18，-4.14±1.32，p=0.041). 
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Figure 3.11 Correlation between all gene expression ∆∆Ct and survival. 
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Figure 3.12 Correlation between each gene expression ∆∆Ct and survival.  
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Figure 3.13 Gene expression of the graft after cardiac xenotransplantation. Groups differ by 
survival of more or less than 40 days. (*p＜0.05)
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3.5 Correlation between gene expression and laboratory markers 
Correlation of gene expression with laboratory results was tested, there were two 
significant results. IL-5 gene expression strongly correlated with troponin T (r = 
0.8059; p =0.0005) (Figure 3.14.a). IL-1β fold change correlated with IL-6 serum 
concentration ( r = 0.6581; p =0.0105) (Figure 3.14.b). 
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Figure 3.14 Correlation between IL-5 gene expression and serum concentration of troponin T 
(a); the correlation between IL-1βgene expression and serum concentration of IL-6(b). 
Table 3.1 Correlation coefficient r of lab results and gene expression. 
r CRP CK Troponin T WBC IL6 Neutrophils Lymphocyte 
IL-4 0.237 0.221 0.361 0.199 0.069 0.174 0.106 
IL-5 0.538 0.266 0.806 -0.009 -0.160 0.100 -0.275 
IL-6 -0.024 0.182 -0.113 -0.025 0.346 0.037 -0.336 
IL-10 0.031 0.364 -0.103 0.389 0.422 0.404 -0.187 
IL-8 -0.080 0.303 -0.176 0.265 0.518 0.251 -0.119 
TNF-α 0.051 0.283 -0.153 0.305 0.500 0.261 0.074 
IL-1α -0.063 0.193 -0.149 0.141 0.405 0.115 -0.087 
IL-1β -0.100 0.539 -0.014 0.345 0.658 0.320 -0.066 
 
Table 3.2 Correlation p of lab results and gene expression. 
p CRP CK Troponin T WBC IL6 Neutrophils Lymphocyte 
IL-4 0.414 0.448 0.226 0.494 0.824 0.552 0.719 
IL-5 0.032 0.319 0.0005 0.975 0.568 0.714 0.302 
IL-6 0.931 0.501 0.700 0.926 0.207 0.891 0.204 
IL-10 0.923 0.245 0.777 0.212 0.172 0.193 0.561 
IL-8 0.768 0.254 0.546 0.322 0.048 0.349 0.660 
TNF-α 0.851 0.289 0.600 0.250 0.058 0.328 0.787 
IL-1α 0.818 0.474 0.611 0.602 0.134 0.671 0.748 
IL-1β 0.722 0.038 0.965 0.208 0.011 0.244 0.815 
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3.6 Pro-inflammatory and anti-inflammatory 
There was no statistically significant difference between all pro- and anti-
inflammatory cytokine gene expressions together (Figure 3.15). There were 
significant correlations between ∆∆Ct of both pro- and anti-inflammatory genes and 
days of survival (Figure 3.16). 
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Figure 3.15 No significant difference was found between pro-inflammatory and anti-
inflammatory gene expression. 
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Figure 3.16 Correlation between survival and pro-inflammatory and anti-inflammatory gene 
expression. 
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3.7 Acute-inflammatory and chronic-inflammatory 
There was no significant difference between acute and chronic inflammatory 
cytokines (Figure 3.17). Gene expression of both acute inflammatory (r=-0.604, 
p=0.035) and chronic inflammatory (r=-0.604, p=0.007) cytokines correlated with 
survival time (Figure 3.18).  
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Figure 3.17 No significant difference was found between the acute-inflammatory and chronic-
inflammatory gene expression. 
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Figure 3.18 Correlation between acute inflammation and chronic inflammation gene 
expression and survival. 
3.8 Heart preservation 
Grouped by different heart preservation methods during transplantation, IL-
5(47.78±52.06，2.882±5.091，p=0.0068) and IL-6(73.61±84.77，0.9288±1.320，
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p=0.0063) gene expression were significantly different (Figure 3.19). No difference in 
RQ was found in other inflammatory genes between these groups. 
3.9 Temsirolimus treatment 
Temsirolimus was administrated in experiments from PAV10 to PAV16. Comparing 
these experiments, the expression of the inflammatory gene IL-1β (3.153±2.789，
0.02398±0.03214，p=0.0112) was significantly reduced. In contrast, there was no 
significant difference in fold change of other genes before and after using 
temsirolimus (Figure 3.20). 
 
39 
 
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
IL-4
R
Q
ns
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
IL-5
R
Q
✱✱
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
IL-6
R
Q
✱✱
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
IL-10
R
Q
ns
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
IL-8
R
Q
ns
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
TNF-α
R
Q
ns
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
IL-1α
R
Q
ns
Ischaemic Non-ischaemic
0.0001
0.001
0.01
0.1
1
10
100
1000
IL-1β
R
Q
ns
Figure 3.19 Experiments grouped by ischemic or non-ischemic heart preservation, significant 
differences were found in IL-5 and IL-6 gene expression. (**p＜0.01) 
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Figure 3.20 Only IL-1β gene expression was found a significant difference between non-
temsirolimus and temsirolimus groups. (*p＜0.05） 
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4. Discussion 
Some of the results from our pig-to-baboon orthotopic heart transplantation 
experiments have been published elsewhere, especially with respect to the overall 
survival of the recipients and the specific experimental model [88]. Briefly, the 
application of non-ischemic heart preservation method during the transplantation 
resulted in the first milestone of our experimental progress, preventing early 
perioperative graft failure. Xenograft overgrowth, which was shown to cause graft 
failure within the first postoperative weeks, could be inhibited mainly by adding 
another immunosuppressive agent, temsirolimus, to the original treatment protocol, 
with addition of an antihypertensive treatment regimen and the fast tapering down of 
corticosteroids. Thus, consistent survival times of more than 90 days – in two cases 
more than 6 months – could be achieved. These results not only bring 
xenotransplantation closer to the clinical application but may also have beneficial 
impact on human allotransplantation. 
4.1 Systemic inflammatory markers and cardiac markers 
Just as researchers gradually overcome the problem of graft rejection and other 
barriers, the inflammatory response after surgery turns into one of the puzzles that 
need to be solved. Taking together clinical and experimental results, we are aware of 
the inflammatory response that is triggered after cardiac xenotransplantation [64]. 
There is increasing evidence of a sustained state of systemic inflammation following 
xenotransplantation of pig-to-nonhuman primate [89].  
CRP is the most common systemic inflammatory marker measured in clinical practice. 
In only two experiments the serum CRP was elevated on the last day of the study, 
whereas CRP was within normal ranges in all other experiments. These observations 
indicate that in most experiments no major systemic inflammation was present at that 
time. In the case of CRP elevation, it is unclear whether the development of the 
inflammatory response was caused by a primary xeno-immune response or a 
secondary response to a surgical injury.  
WBC count is, like CRP, an important clinical marker of inflammation. White blood 
cells, including lymphocytes and neutrophils, recognize and destroy invading 
pathogens, such as bacteria. A high level of WBC may imply a bacterial infection but 
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also a state of stress, trauma or allergy. In our recipients, however, the absolute 
WBC, Lymphocyte and neutrophil counts on the last day were normal, except for 
PAV4, PAV6, PAV7, and PAV8. In the longest surviving animals PAV10, PAV12, 
PAV15 and PAV16 WBC counts were normal. We can conclude that there was no 
systematic inflammation in these xenograft recipients before euthanasia, especially 
no strong response in the peripheral blood. Another possible explanation is that we 
administrated full IS regimen in last 7 experiments, which inflammatory cells were 
probably suppressed in these recipients.  
IL-6 is a multifunctional cytokine secreted by various cells, such as T cells, B cells, 
monocytes, fibroblasts, endothelial cells, and cardiac myocytes[90]. This means that 
IL-6 in peripheral blood may come from the donor's heart or from the recipient itself. 
We used human test reagents in the laboratory examination, which detect IL-6 of 
both species in serum. Therefore, we cannot rely on the level of IL-6 serum 
concentration to discriminate between the inflammatory response of the whole body 
or the porcine heart itself. However, the IL-6 gene expression values of the samples 
taken from myocardial tissue should preferably represent the level of the 
inflammatory response of the xenograft itself. In addition, we did not find any 
correlation between IL-6 RQ and serum concentration (see result 3.5), which 
supports this hypothesis. In future research, test kits specific for pigs should be used 
to search for a correlation between pig IL-6 in the serum and gene expression in the 
porcine heart.  
When we correlated the fold change of gene expression and laboratory results, only 
two pairs showed significant correlations. IL-5 and Troponin T have a positive 
correlation (r= 0.806, p= 0.001). Troponin T is a cardiac-specific molecule produced 
after myocardial cell injury and released into the systemic circulation. In a previous 
study, a correlation between troponin T and systemic inflammation markers in 
patients with critical illness has been reported [91]. One possible explanation is a 
troponin T release from cardiomyocytes during systemic inflammation. However, we 
did not find any associations with other inflammation markers, such as IL-6. Because 
both troponin and inflammatory markers have a concentration curve over 
postoperative survival time in the body, it is possibly inaccurate to only use the 
results at the end of the experiment to describe the relationship between them. For a 
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more profound analysis, continuous assessment of serum concentrations and 
sequential biopsies for gene expression analysis would be necessary. 
We calculated the correlation of the serum concentration of IL-6 with the expression 
of each inflammatory gene. Only IL-1β expression proved a positive association with 
IL-6 serum concentration on the last day of experiments. This indirectly indicates that 
in our experiments the systemic inflammation of the recipient animal is not caused by 
the heart. IL-1β and IL-6 both play important roles in inflammation [92, 93]. The 
correlation between heart IL-1β and serum IL-6 is not certain to be caused by the 
same inflammatory stimuli. In addition, we have not found any relationship between 
IL-1β and other systemic inflammation makers. 
4.2 Inflammatory gene expression in the graft 
It is worth noting that there were no differences between the left and right ventricles. 
Likewise, we didn’t find any differences in the gene expression in samples from the 
left or right ventricle. We calculated mean values of left and right ventricles to 
represent the fold change of the genes in our samples.  
With regard to fold changes of the different genes (Figure 3.5), only IL-8 was up-
regulated, all other 7 genes were normally expressed. We can conclude that the pig-
to-baboon xenotransplanted heart does not show a severe inflammatory response at 
the end of the experiment. One reason may be the administration of anti-
inflammatory agents beneficial to prevent or control inflammation. In this respect, the 
IS based on CD40/CD40L costimulation blockade in combination with genetic 
modification of the donor's heart inhibited a relevant inflammation. 
In Ezzelarab’s studies, interestingly, blood IL-8 levels were not elevated after cardiac 
xenotransplantation [42, 89]. Their results show IL-8 levels were elevated with no IS 
and reduced with IS. Their other study indicated that post-transplant levels of IL-8 
were elevated when no anti-inflammatory agents were administered [64]. In our 
experiments, we have administrated IS and anti-inflammatory agents, but IL-8 was 
still upregulated. One reason for these contrasting results may be that we measured 
the expression of IL-8 directly in heart tissue, which may represent the inflammatory 
response of the heart itself. Ezzelarab et al detected IL-8 in the blood, which could be 
a manifestation of systemic inflammation.  
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IL-8 is a potent pro-inflammatory chemokine that plays a primary role in recruiting 
and activating neutrophils in a variety of contexts during inflammation. Research by 
French et al implies that porcine and human IL-8 activate human neutrophils and 
boost adhesion to endothelial pig aortic cells [63]. In their experiments, Reparixin (IL-
8/ CXCL8 receptor blocker) was used to inhibit the IL-8 pathway in lung 
xenotransplantation experiments. To our knowledge, there are no studies considering 
this aspect of heart xenotransplantation. Our work implicates that IL-8 is a possible 
factor in mediating xenograft inflammation worth more thorough research. 
In 12 of 16 experiments, there was a statistically significant difference between gene 
expression results from xenotransplanted porcine heart and those from non-
transplanted hearts. PAV5 was the only with significantly up-regulated genes. PAV5 
was an early experiment when the non-ischemic heart preservation method just had 
been implemented and no temsirolimus was administrated. PAV11, PAV12, and 
PAV16 had down-regulated gene expressions. For these experiments non-ischemic 
heart preservation methods were used and both CK and troponin T were in normal 
ranges which proved their xenografts were well preserved. It seems probable that the 
combination of an optimized IS regimen with the administration of anti-inflammatory 
agents in these experiments was instrumental for achieving the results mentioned 
above. 
4.3 Postoperative survival 
According to our results, gene expression of inflammatory cytokines was negatively 
correlated with survival time. That means that these genes were overexpressed in 
baboons with short survival and less expressed in those with longer survival. 
Especially for IL-1β, the lowest ∆∆Ct was measured in the two longest surviving 
animals: -10.53, day 182 and -12.06, day 195. 
In order to compare the data, we arbitrarily grouped the experiments by survival time, 
less than 40 days or 40 days and more. The ∆∆Ct of inflammatory genes was 
compared between the two groups. IL-4, IL-6, IL-8, IL-10, IL-1α, and IL-1β expression 
was significantly different between these groups. These results indicate that 
inflammatory responses, both pro-inflammatory and anti-inflammatory, were 
gradually reduced. These inflammatory cytokines play a key role in the defense and 
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repair mechanisms following surgical trauma. In other words, the inflammatory 
reaction gradually decreased as the postoperative rehabilitation progressed.  
However, we still observed a tendency to a gradual decrease of inflammatory gene 
expressions after undergoing perioperative recovery. This is possibly related to the 
sufficient use of anti-inflammatory agents and IS therapy. Some previously findings 
indicate that regulating inflammatory reactions in recipients of xenografts may require 
extra anti-inflammatory treatment that may be crucial for the long-term survival of 
xenograft [64, 94]. However, at the end of the experiment, we did not observe 
elevated systemic or graft inflammation.  
4.4 Pro- and anti-inflammatory, acute and chronic inflammatory 
A sensitive balance between pro- and anti-inflammatory cytokines is preserved in a 
healthy condition. Such homeostasis, however, is interrupted by the surplus elevation 
of pro-inflammatory cytokines in stress states such as trauma [64]. When excess pro-
inflammatory cytokines are released, anti-inflammatory cytokines are secreted 
eventually to restore the equilibrium. Our results show that pro- and anti-inflammatory 
gene expressions are similar at the end of the experiment. As described above, both 
pro- and anti-inflammatory responses gradually decreased as recovery progressed. 
We believe it may be related to the administrated of IS regimens and anti-
inflammatory agents.  
In cardiac xenotransplantation, the advancement of IS regimens and genetical 
modifications have improved outcomes over recent years. Many studies have 
emphasized that the strategy of anti-inflammatory agents is increasingly important for 
postoperative survival [64, 89].  But before we draw any conclusion, administration of 
IS and other treatments cannot be ignored. To study this more thoroughly, single 
variable research would be a good choice. For example, monitoring inflammatory 
response while changing the anti-inflammatory drug or dose in a xenograft in which 
immunological tolerance has been obtained. In preclinical baboon experiments this 
approach is difficult to realize and other models might be needed. 
No statistical difference was found between acute and chronic inflammatory-related 
gene expressions. This might be because our recipient animals did not have severe 
systemic or local inflammation. We also found a correlation with survival days, which 
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indicates that acute inflammation and chronic inflammatory response decrease with 
postoperative survival time. Therefore, the early postoperative inflammatory response 
is most likely due to surgical trauma or acute immune response and gradually 
decreases with treatment and rehabilitation. 
4.5 Heart preservation 
The different heart preservation methods during the surgery had a significant 
influence on IL-5 and IL-6 expression. Gene expression for both cytokines was lower 
in the group of non-ischaemic perfused hearts. Myocardial ischemia is known to 
induce IL-6 production in human patients [95]. Similar to other inflammatory reactions, 
CD4+ TH1 cells may play a key role in the pathogenesis of ischemia through 
releasing pro-inflammatory cytokines, whereas CD4+ TH2 cells may play a protective 
role through anti-inflammatory cytokines such as IL-5 [96]. In our study, the samples 
were taken from the animal on the last day of survival. However, survival in the 
ischemic group was very short (PAV2, PAV4, and PAV6 were survival one day) and 
upregulation during the transplantation process can only be seen in this group. In 
further experiments, the immediate inflammatory gene expression could be 
measured by myocardial biopsies to prove the difference between the two different 
heart preservation methods. 
4.6 Temsirolimus treatment 
Starting with PAV 10, temsirolimus was added to maintenance immunosuppression. 
Temsirolimus mitigates myocardial hypertrophy in our heart xenotransplantation 
model [88]. In our experiments, temsirolimus reduced IL-1β expression, whereas no 
influence on other inflammatory genes was observed. Jia et al demonstrated that 
temsirolimus is able to inhibit the production and secretion of IL-1β in mice [97]. As 
mentioned above, IL-1β was positively correlated with survival time, thus the role of 
temsirolimus in this experiment may also be related to inhibition of IL-1β, not just the 
control of heart overgrowth.  
4.7 Conclusion 
Inflammation may play an important role in prolonging the survival time after cardiac 
xenotransplantation. We did not find intense systemic inflammation caused by 
inflammatory processes in the graft of 16 recipient animals. IL-8 was up-regulated 
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after transplantation, and likely plays a potent role in mediating xenograft 
inflammation. IL-4, IL-10 and IL-1β expression had a significant correlation with 
longer postoperative survival time. Especially IL-1β may be used as a target to 
reduce inflammation and increase survival. This study highlights the utility of gene 
expression analysis to monitor inflammation after xenotransplantation and to identify 
new potential markers that contribute to cardiac xenotransplantation research. 
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Summary 
Inflammatory cytokines have important effects on organ transplantation. However, 
their role in cardiac xenotransplantation remains elusive. The aim of this study was to 
explore inflammatory gene expression associated with an orthotopic cardiac 
xenotransplantation model with genetically modified pigs as organ donors. 
16 genetically modified pig hearts (GTKO, hCD46, hTM) were orthotopically 
transplanted into baboons. Ischemic (n=4) or non-ischemic (n=12) heart preservation 
methods were performed during operation. Immunosuppression was based on 
steroids, MMF, and CD40/CD40L blockade. Treatment for growth inhibition including 
temsirolimus was administrated in seven experiments. IL6, C-reactive protein (CRP), 
creatinine kinase (CK), troponin T concentration and WBC (including neutrophils and 
lymphocytes) count were measured at the end of the experiments.  
Snap frozen myocardial samples were collected from the grafts immediately post 
mortem. The total RNA was extracted from 20~30mg of tissue and reverse 
transcripted to cDNA. The expression of associated inflammatory genes Interleukin 1 
alpha (IL-1α), IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10 and tumor necrosis factor α (TNF-α) 
were measured using quantitative real-time polymerase chain reaction (qPCR). Gene 
expression was compared to control, not transplanted pig hearts, and relative gene 
expression was analysed.  
The mean survival of baboons was 61.3 [1-195] days. On the last day of the 
experiments, the mean serum concentration of IL6 was 1475 ± 4819 pg/ml, the CRP 
concentration was 2.1 ± 2.1 mg/dl, CK concentration was 6599 ± 9708 IU/L. IL-8 was 
upregulated as compared to control. Comparative analysis of gene expression 
between left and right ventricle for each experiment revealed no significant difference. 
There were significant correlations between survival days and ∆∆Ct of IL-4, IL-10, 
and IL-1β. Gene expressions of IL-4, IL-6, IL-8, IL-10, IL-1α, and IL-1β showed 
significant differences between groups of more and less than 40 days of survival. A 
strong correlation was found between IL-5 and troponin T. IL-1β fold change and IL-6 
serum concentration also have a positive correlation. Grouped by different heart 
preservation methods during transplantation, IL-5 and IL-6 gene expression were 
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significantly different. The expression of IL-1β was significantly reduced by using 
temsirolimus. 
Non-ischaemic heart preservation method and administration of temsirolimus 
significantly reduced inflammation in xenotransplant heart. Correlation analysis 
indicated that a significant correlation between inflammatory cytokines gene 
expression and postoperative survival time. Inflammatory processes in the graft did 
not lead to measurable systemic inflammation.  
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Zusammenfassung 
 
Inflammatorische Zytokine haben wichtige Auswirkungen auf Organtransplantationen. 
Dennoch bleibt ihre Rolle in der Xenotransplantation von Herzen unklar. Das Ziel 
dieser Studie war es, die in einem orthotopen Xenotransplantationsmodell mit 
genetisch modifizierten Schweinen als Organspender assoziierte inflammatorische 
Genexpression zu untersuchen. 
16 genetisch modifizierte Schweineherzen (GTKO, hCD46, hTM) wurden orthotop in 
Paviane transplantiert. Die Spenderherzen wurden während der Operation entweder 
ischämisch (n=4) oder nicht-ischämisch (n=12) präserviert. Die Immunsuppression 
basierte auf Steroiden, MMF und CD40-/CD40L- Blockade. In sieben der 16 
Experimenten wurde zusätzlich das Wachstum des Spenderherzens mittels 
Temsirolimus gehemmt. Die Konzentration von IL-6, C-reaktivem Protein (CRP), 
Kreatinkinase (CK), Troponin T und die Anzahl weißer Blutzellen (inklusive 
Neutrophilen und Lymphozyten) wurden am Ende der Experimente gemessen.  
Unmittelbar post mortem wurden gefriergetrocknete Myokardproben entnommen. 
RNA wurde aus 20-30mg großen Gewebeproben extrahiert und durch reverse 
Transkription in cDNA umgeschrieben. Die Expression der inflammatorischen Gene 
Interleukin 1 alpha (IL-1α), IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10 und Tumornekrosefaktor 
α (TNF-α) wurden mittels quantitativer Polymerase-Kettenreaktion (qPCR) gemessen. 
Als Kontrolle dienten nicht-transplantierte Schweineherzen. Die ermittelte 
Genexpression wurde mit der Kontrolle verglichen und die relative Genexpression 
analysiert. 
Die mittlere Überlebensdauer der Paviane war 61.3 [1-195] Tage. Am letzten Tag der 
Experimente betrugen die Serumkonzentrationen von IL6 1475 ± 4819 pg/ml, von 
CRP 2.1 ± 2.1 mg/dl und von CK 6599 ± 9708 IU/L. IL-8 war im Vergleich zur 
Kontrolle hochreguliert. Vergleichende Analysen der Genexpression des linken und 
rechten Ventrikels für jedes Experiment zeigten keine signifikanten Unterschiede. Die 
Überlebenszeit korrelierte signifikant mit ∆∆Ct von IL- 4, IL-10 und IL-1β. Die 
Genexpressionen von IL-4, IL-6, IL-8, IL-10, IL-1α und IL-1β waren signifikant 
unterschiedlich zwischen  den Gruppen mit mehr und weniger als 40 
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Überlebenstagen. Es zeigte sich eine starke Korrelation zwischen IL-5 und Troponin 
T. Ebenfalls positiv korrelierte die IL-6 Serumkonzentration mit der Fold Change von 
IL-1β. Gruppiert nach unterschiedlichen Organpräservationsmethoden während der 
Transplantation zeigte sich ein signifikanter Unterschied der Genexpression von IL-5 
und IL-6. Die Expression von IL-1β wurde durch den Gebrauch von Temsirolimus 
signifikant reduziert. 
Die nicht-ischämische Methode der Herzpräservation und der Einsatz von 
Temsirolimus reduzierten die Inflammation in xenotransplantierten Herzen signifikant. 
Korrelationsanalysen ergaben eine signifikante Korrelation zwischen 
inflammatorischen Zytokinen und postoperativer Überlebenszeit. Inflammatorische 
Prozesse im Graft führen nicht zu einer messbaren systemischen Inflammation.  
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